Dr. David E. Stickler, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- West Virginia University School of Medicine (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 432
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: West Virginia University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
SC license 28323
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Musc Medical Center Charleston, SC
- Lexington Medical Center West Columbia, SC
- Roper Hospital Charleston, SC
- Roper St Francis Hospital-Berkeley Inc Summerville, SC
Medical groups
- Pain Specialists of Charleston (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 432
- Services billed
- 1,042
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Needle measurement of electrical activity in arm or leg muscles, complete study | 391 | 242 |
| Established patient office or other outpatient visit, 20-29 minutes | 315 | 209 |
| Established patient office or other outpatient visit, 30-39 minutes | 94 | 69 |
| Nerve conduction, 5-6 studies | 68 | 68 |
| Nerve conduction, 3-4 studies | 66 | 66 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 54 | 44 |
| New patient office or other outpatient visit, 30-44 minutes | 49 | 49 |
| Nerve conduction, 7-8 studies | 47 | 47 |
| Nerve conduction, 13 or more studies | 28 | 28 |
| Nerve conduction, 9-10 studies | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in North Charleston, SC | 84 |
| Gabapentin Other prescribers in North Charleston, SC | 81 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in North Charleston, SC | 76 |
| Prednisone Other prescribers in North Charleston, SC | 70 |
| Pyridostigmine Bromide Other prescribers in North Charleston, SC | 58 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 52 |
| Levetiracetam Other prescribers in North Charleston, SC | 44 |
| Topiramate Other prescribers in North Charleston, SC | 39 |
| Primidone Other prescribers in North Charleston, SC | 38 |
| Mycophenolate Mofetil Other prescribers in North Charleston, SC | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $124 in total to this clinician.
| AbbVie Inc. | $124 |
|---|
| Food and Beverage | $124 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $314,943 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myastheni…
Ares Trading SA - A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. - Study name not reported
Lexicon Pharmaceuticals, Inc. - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
AbbVie Inc. · Terminated · NCT05028569 - A Phase 2b/3 Adaptive, Randomized, Placebo-controlled, Double-blind Study Evaluating the Efficacy, Safety and Tolerability of Povetacicept for Treatment of Generalized Myasthenia Gravis
Vertex Pharmaceuticals Incorporated - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy?
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.